Sulfate Radical Based In Situ Vaccine Boosts Systemic Antitumor Immunity via Concurrent Activation of Necroptosis and STING Pathway
Advanced Materials · 2024
DOI: 10.1002/adma.202407914 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Yiming Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medicine Scientific and Technical Innovation Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 20009…. Hauptthemen laut MEDLINE: Necroptosis, Cancer Vaccines, Sulfates, Membrane Proteins. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Shanghai Natural Science Foundation Project, Australian National Health and Medical Research Council.
Abstract (Originalsprache)
In situ vaccine (ISV) can provoke systemic anti‐tumor immunity through the induction of immunogenic cell death (ICD). The development of ISV technology has been restricted by the limited and suboptimal ICD driven tumor antigen production which are currently relying on chemo‐drugs, photo‐/radio‐sensitizers, oncolytic‐virus and immunostimulatory agents. Herein, a sulfate radical (SO 4 ·− ) based ISV is reported that accomplishes superior tumor immunotherapy dispense from conventional approaches. The ISV denoted as P‐Mn‐LDH is constructed by intercalating peroxydisulfate (PDS, a precursor of SO 4 ·− ) into manganese layered double hydroxide nanoparticles (Mn‐LDH). This design allows the stabilization of PDS under ambient condition, but triggers a Mn 2+ mediated PDS decomposition in acidic tumor microenvironment (TME) to generate in situ SO 4 ·− . Importantly, it is found that the SO 4 ·‐ radicals not only effectively kill cancer cells, but also induce a necroptotic cell death pathway, leading to robust ICD signaling for eliciting adaptive immunity. Further, the P‐Mn‐LDH can activate the stimulator of interferon genes (STING) pathway to further boost anti‐tumor immunity. Collectively, the P‐Mn‐LDH based ISV exhibited potent activity in inhibiting tumor growth and lung metastasis. When combined with immune checkpoint inhibitor, significant inhibition of distant tumors is achieved. This study underpins the promise of SO 4 ·‐ based vaccine technology for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Medicine Scientific and Technical Innovation Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200092, P. R. China.
- Shanghai Frontiers Science Research Base of Intelligent Optoeletronics and Perception Institute of Optoelectronics, Fudan University, Shanghai, 200433, P. R. China.
- South Australian immunoGENomics Cancer Institute, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, 5005, Australia.
ORCID-Profile: Yannan Yang
Förderung
- Shanghai Natural Science Foundation Project
- Australian National Health and Medical Research Council
Zitieren
APA
Huang, Y., Zou, J., Huo, J., Zhang, M., & Yang, Y. (2024). Sulfate Radical Based In Situ Vaccine Boosts Systemic Antitumor Immunity via Concurrent Activation of Necroptosis and STING Pathway. Advanced Materials. https://doi.org/10.1002/adma.202407914
Vancouver
Huang Y, Zou J, Huo J, Zhang M, Yang Y. Sulfate Radical Based In Situ Vaccine Boosts Systemic Antitumor Immunity via Concurrent Activation of Necroptosis and STING Pathway. Advanced Materials. 2024. doi:10.1002/adma.202407914
BibTeX
@article{Huang2024,
author = {Huang, Yiming and Zou, Jie and Huo, Jiangyan and Zhang, Min and Yang, Yannan},
title = {Sulfate Radical Based In Situ Vaccine Boosts Systemic Antitumor Immunity via Concurrent Activation of Necroptosis and STING Pathway},
journal = {Advanced Materials},
year = {2024},
doi = {10.1002/adma.202407914}
}
EUVIMED